New TGRX-678 pill for chronic-phase CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new targeted therapy pill (TGRX-678) for adults with chronic-phase CML who no longer benefit from or cannot tolerate at least three other targeted therapies. The goal is to see if this drug can control the leukemia better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic-phase CML and have tried at least 3 TKIs (targeted therapy pills) with poor results or side effects.
- Your general health is good enough to get around (ECOG 0-2, meaning you can care for yourself).
- Your blood counts, kidney, liver, and heart tests are within acceptable ranges.
- You have not used blood transfusions or growth factors recently, and you are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial tests a new drug combination (HS-10382 plus another drug) for people with chronic myeloid leukemia (CML) whose current treatments have stopped working or caused side effects. It may help if you have a certain type of CML that is not controlled by previous therapies.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.